Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference45 articles.
1. Tanimoto T, Tsubokura M, Mori J, Pietrek M, Ono S, Kami M. Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin. Investig New Drugs. 2013;31:473–478.
2. Marijon E, Le Heuzey JY, Fauchier L. Review of novel therapeutics by three regulatory agencies. N Engl J Med. 2012;367:1166; author reply 1166-1167.
3. Garbe E, Andersohn F. Contraindication labelling changes in the United States and Germany. Eur J Clin Pharmacol. 2007;63:87–93.
4. Malinowski HJ, Westelinck A, Sato J, Ong T. Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan. J Clin Pharmacol. 2008;48:900–908.
5. Balant LP, Balant-Gorgia EA. Cultural differences: implications on drug therapy and global drug development. Int J Clin Pharmacol Ther. 2000;38:47–52.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献